PMC:7205724 / 467-687 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"11","span":{"begin":32,"end":40},"obj":"Disease"},{"id":"17","span":{"begin":66,"end":69},"obj":"Gene"},{"id":"18","span":{"begin":125,"end":128},"obj":"Gene"},{"id":"19","span":{"begin":93,"end":101},"obj":"Species"},{"id":"20","span":{"begin":45,"end":56},"obj":"Chemical"},{"id":"21","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"53","span":{"begin":144,"end":161},"obj":"Species"},{"id":"54","span":{"begin":163,"end":172},"obj":"Species"},{"id":"65","span":{"begin":198,"end":211},"obj":"Disease"}],"attributes":[{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Gene:3569"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Gene:3569"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:9606"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:C502936"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:C000657245"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:2697049"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D034062"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T4","span":{"begin":32,"end":40},"obj":"Disease"},{"id":"T5","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"T6","span":{"begin":163,"end":167},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":184,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T2","span":{"begin":3,"end":13},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A2","pred":"meddra_id","subj":"T2","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T2","span":{"begin":204,"end":211},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T4","span":{"begin":32,"end":40},"obj":"Species"},{"id":"T5","span":{"begin":107,"end":115},"obj":"Species"},{"id":"T6","span":{"begin":163,"end":172},"obj":"Species"}],"attributes":[{"id":"A4","pred":"ncbi_taxonomy_id","subj":"T4","obj":"NCBItxid:2697049"},{"id":"A5","pred":"ncbi_taxonomy_id","subj":"T5","obj":"NCBItxid:2697049"},{"id":"A6","pred":"ncbi_taxonomy_id","subj":"T6","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T9","span":{"begin":42,"end":129},"obj":"Sentence"},{"id":"T10","span":{"begin":131,"end":139},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"11","span":{"begin":32,"end":40},"obj":"Disease"},{"id":"20","span":{"begin":45,"end":56},"obj":"Chemical"},{"id":"17","span":{"begin":66,"end":69},"obj":"Gene"},{"id":"19","span":{"begin":93,"end":101},"obj":"Species"},{"id":"21","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"18","span":{"begin":125,"end":128},"obj":"Gene"},{"id":"53","span":{"begin":144,"end":161},"obj":"Species"},{"id":"54","span":{"begin":163,"end":172},"obj":"Species"},{"id":"65","span":{"begin":198,"end":211},"obj":"Disease"}],"attributes":[{"id":"A11","pred":"pubann:denotes","subj":"11","obj":"MESH:C000657245"},{"id":"A17","pred":"pubann:denotes","subj":"17","obj":"Gene:3569"},{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"MESH:C502936"},{"id":"A54","pred":"pubann:denotes","subj":"54","obj":"Tax:2697049"},{"id":"A53","pred":"pubann:denotes","subj":"53","obj":"Tax:2697049"},{"id":"A19","pred":"pubann:denotes","subj":"19","obj":"Tax:9606"},{"id":"A65","pred":"pubann:denotes","subj":"65","obj":"MESH:D034062"},{"id":"A18","pred":"pubann:denotes","subj":"18","obj":"Gene:3569"},{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"MESH:C000657245"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T45","span":{"begin":66,"end":69},"obj":"Protein"},{"id":"T89","span":{"begin":125,"end":128},"obj":"Protein"}],"attributes":[{"id":"A45","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A46","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A47","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A48","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A49","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A50","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A51","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A52","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A53","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A54","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A55","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A56","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A57","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A58","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A59","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A60","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A61","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A62","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A63","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A64","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A65","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A66","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A67","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A68","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A69","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A70","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A71","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A72","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A73","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A74","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A75","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A76","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A77","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A78","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A79","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A80","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A81","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A82","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A83","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A84","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A85","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A86","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A87","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A88","pred":"uniprot_id","subj":"T45","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A89","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A90","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A91","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A92","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A93","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A94","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A95","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A96","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A97","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A98","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A99","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A100","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A101","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A102","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A103","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A104","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A105","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A106","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A107","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A108","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A109","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A110","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A111","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A112","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A113","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A114","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A115","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A116","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A117","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A118","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A119","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A120","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A121","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A122","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A123","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A124","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A125","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A126","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A127","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A128","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A129","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A130","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A131","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A132","pred":"uniprot_id","subj":"T89","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T67","span":{"begin":1,"end":2},"obj":"-COMMA-"},{"id":"T68","span":{"begin":3,"end":8},"obj":"JJ"},{"id":"T69","span":{"begin":9,"end":13},"obj":"NN"},{"id":"T70","span":{"begin":13,"end":14},"obj":"-COMMA-"},{"id":"T71","span":{"begin":15,"end":18},"obj":"CC"},{"id":"T72","span":{"begin":19,"end":28},"obj":"NN"},{"id":"T73","span":{"begin":29,"end":31},"obj":"IN"},{"id":"T74","span":{"begin":32,"end":40},"obj":"NN"},{"id":"T75","span":{"begin":42,"end":43},"obj":"IN"},{"id":"T76","span":{"begin":45,"end":56},"obj":"NNP"},{"id":"T77","span":{"begin":56,"end":57},"obj":"-COMMA-"},{"id":"T78","span":{"begin":58,"end":60},"obj":"DT"},{"id":"T79","span":{"begin":61,"end":69},"obj":"NN"},{"id":"T80","span":{"begin":69,"end":70},"obj":"-COMMA-"},{"id":"T81","span":{"begin":71,"end":74},"obj":"MD"},{"id":"T82","span":{"begin":75,"end":81},"obj":"VB"},{"id":"T83","span":{"begin":82,"end":89},"obj":"NN"},{"id":"T84","span":{"begin":90,"end":92},"obj":"IN"},{"id":"T85","span":{"begin":93,"end":101},"obj":"NNS"},{"id":"T86","span":{"begin":102,"end":106},"obj":"IN"},{"id":"T87","span":{"begin":107,"end":115},"obj":"NN"},{"id":"T88","span":{"begin":116,"end":119},"obj":"CC"},{"id":"T89","span":{"begin":120,"end":124},"obj":"JJ"},{"id":"T90","span":{"begin":125,"end":128},"obj":"NN"},{"id":"T91","span":{"begin":131,"end":139},"obj":"NN"},{"id":"T92","span":{"begin":140,"end":143},"obj":"DT"},{"id":"T93","span":{"begin":144,"end":149},"obj":"JJ"},{"id":"T94","span":{"begin":150,"end":161},"obj":"NN"},{"id":"T95","span":{"begin":161,"end":162},"obj":"-COMMA-"},{"id":"T96","span":{"begin":163,"end":172},"obj":"NN"},{"id":"T97","span":{"begin":172,"end":173},"obj":"-COMMA-"},{"id":"T98","span":{"begin":174,"end":177},"obj":"MD"},{"id":"T99","span":{"begin":178,"end":183},"obj":"VB"},{"id":"T100","span":{"begin":184,"end":185},"obj":"DT"},{"id":"T101","span":{"begin":186,"end":197},"obj":"RB"},{"id":"T102","span":{"begin":198,"end":203},"obj":"JJ"},{"id":"T103","span":{"begin":204,"end":211},"obj":"NN"},{"id":"T104","span":{"begin":211,"end":212},"obj":"-COMMA-"}],"relations":[{"id":"R62","pred":"arg2Of","subj":"T69","obj":"T67"},{"id":"R63","pred":"arg1Of","subj":"T69","obj":"T68"},{"id":"R64","pred":"arg1Of","subj":"T71","obj":"T70"},{"id":"R65","pred":"arg1Of","subj":"T67","obj":"T71"},{"id":"R66","pred":"arg2Of","subj":"T72","obj":"T71"},{"id":"R67","pred":"arg1Of","subj":"T72","obj":"T73"},{"id":"R68","pred":"arg2Of","subj":"T74","obj":"T73"},{"id":"R69","pred":"arg1Of","subj":"T82","obj":"T75"},{"id":"R70","pred":"arg1Of","subj":"T76","obj":"T77"},{"id":"R71","pred":"arg2Of","subj":"T79","obj":"T77"},{"id":"R72","pred":"arg1Of","subj":"T79","obj":"T78"},{"id":"R73","pred":"arg1Of","subj":"T82","obj":"T80"},{"id":"R74","pred":"arg1Of","subj":"T76","obj":"T81"},{"id":"R75","pred":"arg2Of","subj":"T82","obj":"T81"},{"id":"R76","pred":"arg1Of","subj":"T76","obj":"T82"},{"id":"R77","pred":"arg2Of","subj":"T83","obj":"T82"},{"id":"R78","pred":"arg1Of","subj":"T82","obj":"T84"},{"id":"R79","pred":"arg2Of","subj":"T85","obj":"T84"},{"id":"R80","pred":"arg1Of","subj":"T85","obj":"T86"},{"id":"R81","pred":"arg2Of","subj":"T88","obj":"T86"},{"id":"R82","pred":"arg1Of","subj":"T87","obj":"T88"},{"id":"R83","pred":"arg2Of","subj":"T90","obj":"T88"},{"id":"R84","pred":"arg1Of","subj":"T90","obj":"T89"},{"id":"R85","pred":"arg1Of","subj":"T94","obj":"T92"},{"id":"R86","pred":"arg1Of","subj":"T94","obj":"T93"},{"id":"R87","pred":"arg1Of","subj":"T94","obj":"T95"},{"id":"R88","pred":"arg2Of","subj":"T96","obj":"T95"},{"id":"R89","pred":"arg1Of","subj":"T99","obj":"T97"},{"id":"R90","pred":"arg1Of","subj":"T94","obj":"T98"},{"id":"R91","pred":"arg2Of","subj":"T99","obj":"T98"},{"id":"R92","pred":"arg1Of","subj":"T94","obj":"T99"},{"id":"R93","pred":"arg2Of","subj":"T103","obj":"T99"},{"id":"R94","pred":"arg1Of","subj":"T103","obj":"T100"},{"id":"R95","pred":"arg1Of","subj":"T102","obj":"T101"},{"id":"R96","pred":"arg1Of","subj":"T103","obj":"T102"},{"id":"R97","pred":"arg1Of","subj":"T103","obj":"T104"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T4","span":{"begin":32,"end":40},"obj":"Disease"},{"id":"T5","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"T6","span":{"begin":163,"end":172},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":42,"end":129},"obj":"Sentence"},{"id":"T10","span":{"begin":131,"end":139},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"y, viral load, and prognosis of COVID-19.\n• Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6.\n\nAbstract\nThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-1"}